The Impact of Psychopharmacology on Contemporary Psychiatry by Baldessarini, Ross J
 




(Article begins on next page)
The Harvard community has made this article openly
available.
Please share how this access benefits you. Your story
matters.
Citation Baldessarini, Ross J. 2014. “The Impact of
Psychopharmacology on Contemporary Psychiatry.” Canadian
Journal of Psychiatry. Revue Canadienne de Psychiatrie 59 (8):
401-405.
Accessed February 16, 2015 9:08:11 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785918
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and
conditions applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAwww.TheCJP.ca The Canadian Journal of Psychiatry, Vol 59, No 8, August 2014   W   401
CanJPsychiatry 2014;59(8):401–405
Key Words: drug development; 
psychiatric education, practice, 
theory; psychopharmacology
Received and accepted May 
2014.
The Impact of Psychopharmacology on Contemporary 
Psychiatry
Ross J Baldessarini, MD1
1 Professor of Psychiatry and in Neuroscience, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts; Founding Director, International 
Bipolar & Psychotic Disorder Research Consortium, Mailman Research Center, McLean Hospital, Boston, Massachusetts. 
Correspondence: Mailman Research Center, McLean Hospital, 15 Mill Street, Belmont, MA  02478-9106; rbaldessarini@mclean.harvard.edu.
M
odern clinical psychopharmacology can be dated from the introduction of lithium 
carbonate to treat mania by John Cade in Australia in 1949 or from the introduction 
of chlorpromazine as the first synthetic drug found to be effective in both mania and 
psychotic disorders in Paris in the early 1950s. Soon thereafter, the mood-elevating 
effects of the monoamine oxidase inhibitor, iproniazid, and the antidepressant effects of 
imipramine were reported. By 1960, haloperidol, the first butyrophenone antipsychotic, 
the first so-called atypical antipsychotic, clozapine, and the benzodiazepines also were 
introduced.1 That is, at least one agent from each major class of currently employed 
psychotropic drugs was known by the end of the 1950s. These new treatments brought 
about fundamental changes in the treatment of many major psychiatric disorders of 
unknown cause—notably, mania, depression, acute and chronic psychotic disorders, 
including schizophrenia, as well as severe anxiety disorders. These changes can fairly 
be considered revolutionary. Moreover, their impact extended far beyond improvements 
in treatment, and included fundamental changes in the conceptualization of most 
psychiatric disorders, in their diagnosis and categorization, on models for research into 
the nature of psychiatric illnesses, on psychiatric education, on methods and standards 
for experimental therapeutics, and on the organization of modern psychiatry as a 
clinical and academic medical specialty.
In the first 2 decades of their introduction into psychiatric therapeutics, there was 
an  intense  struggle  among  the  previous  generation  of  psychiatrists  who  had  been 
captivated by the psychodynamic and psychoanalytic tradition initiated by Sigmund 
Freud and his followers in the early 1900s. A common early assertion was that the 
new drugs might modify symptoms and limit pain and suffering, but left undone much 
of what was required to bring about major and sustained changes in behaviour and 
thinking. Nevertheless, a new generation of more medically or biologically oriented 
psychiatrists came to dominate psychiatry internationally, and to replace their more 
psychologically minded colleagues in positions of influence, including most university 
chairs of psychiatry.
This historical perspective is particularly timely for this issue of The Canadian Journal 
Psychiatry, aimed at a critical assessment of where clinical psychopharmacology and 
its impact on psychiatry now stand. Such sensitive questions arise as to whether the 
pharmacotherapeutic approach may have been overdone, with widespread degradation 
of standards for patient assessment and comprehensive care, as well as deeply affecting 
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psychiatric education and the organization and functioning 
of psychiatric institutions and systems of care delivery.2,3 
As  noted  by  Dr  David  M  Gardner4  and  Dr  Gustavo  H 
Vázquez,5 there has appeared, in recent decades, a growing 
international inclination toward increasingly brief and 
routinized clinical encounters, with an emphasis on rapid 
but  superficial  diagnostic  categorization  and  initiation 
of almost exclusively medicinal treatments. Even if such 
clinical practices were adequate, Dr Gardner4 emphasizes 
that they require extensive training, experience, knowledge, 
and judgment to be used effectively and safely. The argument 
can be made that heavy reliance on medicinal treatments 
with less emphasis on psychological approaches, and on 
symptom checklists rather than on thoughtful understanding 
of each patient has brought about fundamental changes 
in the theory and practice of modern psychiatry. These 
changes involve shifting the balance of tension between 
what has been labelled brainlessness versus mindlessness 
in psychiatry, in the biomedical direction.6,7 Such changes, 
in turn, are consistent with compelling efforts in recent 
decades to manage (limit) the costs of medical care of all 
types. Questions to be considered include whether this 
shift  may  be  antithetical  to  comprehensive,  thoughtful, 
and individualized care of people with psychiatric illness, 
and whether it provides an adequate model for psychiatric 
training.
Another  profound  effect  of  the  introduction  of  effective 
and reasonably safe and tolerated medicinal treatments 
for psychiatric illnesses has been to reframe the tasks 
and possibilities for academic psychiatry and psychiatric 
research in a more biomedical perspective. This shift in 
interest was greatly stimulated by major technical and 
experimental  advances  that  gave  birth  to  the  new  field 
of neuroscience since the 1960s, culminating in recent 
explosive  advances  in  structural  and  functional  brain 
imaging,  behavioural  and  neurogenetics,  and  molecular 
neuroscience.8 The changes in therapeutic practice as well 
as in research orientation marked a return to the 19th-
century tradition of neuromedically oriented and descriptive 
psychiatry—a tradition that became neglected in the 
early-to-mid 20th century.3 A more biomedical approach 
is attractive, but may remain premature, and surely is an 
incomplete basis for understanding of most mental illnesses. 
As increasingly technically sophisticated and detailed 
information is developed in such fields as neuroimaging 
and neurogenetics, we are repeatedly reminded that almost 
all major mental disorders remain fundamentally idiopathic. 
Most lack not only known etiologies but also even a coherent 
pathophysiology. This fundamental truism limits efforts 
to develop a biomedically oriented psychiatry beyond the 
empirical application of psychotropics and detection of 
occasional  coarse  neurological  disorders.  Nevertheless, 
clinical and research efforts to develop a more biomedical 
psychiatry are appropriate and of great, but largely potential 
or even hypothetical, value. Indeed, the history of a series 
of movements in biology and medicine brought to address 
psychiatric disorders during the past 2 centuries is marked 
by time-limited enthusiasm, limited progress, and moving 
on to the next conceptual fashion.9 A point that is directly 
relevant to the present discussion of psychopharmacology 
is that the lack of a pathophysiology, let alone an etiology, 
for most psychiatric illnesses makes rational progress in 
therapeutics extremely difficult and highly risky from both 
a scientific and business perspective.
A fundamental aspect of the great leaps forward of 
psychopharmacology in the unprecedently innovative era 
of the 1950s is that nearly all of the discoveries of novel 
treatments and therapeutic theories rested not on rational 
prediction or laboratory experimentation arising from 
a secure pathological or pathophysiological basis, but 
largely  on  chance  observations  with  immediate  clinical 
implications—that is, the process of serendipity. Examples 
include the surprising clinical effects of lithium carbonate 
when  used  mainly  for  its  putative  anti-gout  activity; 
observations, initially by surgeons and anesthesiologists, 
that  chlorpromazine  was  not  merely  another  sedative; 
unexpected mood changes in tuberculosis sanatoria on 
introduction of the N-isopropyl  analog  of  isoniazid; 
surprising mood changes with imipramine, which looks 
chemically rather like another tricyclic antipsychotic; the 
counter-surprise that clozapine, though chemically rather 
imipraminelike, was not mood-elevating; and there are many 
others.1 A remarkable observation is that serendipity has not 
yet been replaced by modern neurobiology or advances in 
industrial or academic chemistry and neuropharmacology. 
Again, this conclusion follows from the lack of a tissue 
pathology or a plausible pathophysiology for most mental 
disorders.
A consequence of these circumstances is that there 
has  been  remarkably  little  fundamental  innovation  in 
psychopharmacologic therapeutics for psychiatry since the 
early 1960s. Most recently introduced psychotropics are 
modelled on chemical or pharmacodynamic similarities 
to  earlier  predecessors.  This  process  has  provided  a 
viable business model and has led to patentable and often 
highly profitable new drug products, but very little that is 
fundamentally new or improved. In addition, psychotropic 
markets are saturating, patent protection is ending, and 
drug development pipelines are drying up. Indeed, there 
is a growing sense among pharmacological investigators 
and the pharmaceutical industry that we are stuck. In turn, 
a growing number of corporations are shifting investment 
and  resources  away  from  the  central  nervous  system  to 
apparently more tractable clinical problems that have indeed 
witnessed some striking and fundamental innovations in 
recent years.10 A consequence of the lack of innovation in 
psychotropic treatments, as emphasized by Dr Gardner,4 is 
that psychiatry is obliged to redouble efforts to make the best 
use of what we have while hoping for the next therapeutic 
breakthrough—whether guided by scientific theory or again 
through serendipity.
A further effect of the discovery of the several new classes 
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kind of biological theorizing became dominant in academic 
psychiatry—one  that  I  have  termed  pharmacocentric.1,9 
The basic idea is that, as the science of drug action 
(pharmacodynamics)  has  made  initial  small  advances,  it 
has been irresistibly tempting to argue that the opposite of 
the drug action may be a clue to pathophysiology. Among 
other examples, this kind of thinking led to the dopamine-
excess theory of psychotic disorders and mania based 
on the antidopaminergic actions of most antipsychotic-
antimanic  drugs,  to  various  monoamine  deficiency 
hypotheses concerning depression and some anxiety 
disorders based on speculations about the norepinephrine- 
or serotonin-potentiating actions of most antidepressants. 
Although such theorizing stimulated a generation of 
clever  experimentation,  findings  of  research  aimed  at 
testing them at the clinical level has remained inconsistent 
and unconvincing. This outcome should not be any more 
surprising  than,  for  example,  expecting  to  discover  the 
pneumococcus from detailed knowledge of the molecular 
pharmacology of willow bark and its antipyretic salicylates. 
An extension of such speculations sometimes extends into 
clinical practice, as diagnoses or rationales for particular 
treatments are presented to patients couched in concepts 
arising from pharmacodynamics but representing little 
more than neuromythology. Again, the fundamental fact is 
that the disorders considered to lie within the province of 
psychiatry remain idiopathic.
The  changes  outlined  above  have  had  additional, 
fundamental effects on the theory and practice of psychiatry. 
One is that the shift away from 19th-century interests in 
a neurobiology of mental illness was also associated 
with a decline in interest in classic descriptive psychiatry 
and in psychopathology. This loss of interest largely 
continues,  even  in  European  centres  where  the  tradition 
developed.11 It has also been accompanied by some peculiar 
developments  in  both  psychiatric  diagnosis  and  clinical 
practice. Regarding nosology, a former handful of credible 
psychiatric diagnoses12 has grown into a massive collection 
of hundreds of putative disorders to be found in standard 
international diagnostic manuals.13–15 Most of these are 
largely  imperfectly  defined  and  minimally  investigated 
by traditional epidemiologic methods, continue to lack 
a coherent biology, and sometimes prove to be limited in 
clinical and research utility in the face of often complex 
or  atypical  clinical  presentations.  Examples  include  the 
highly unstable group of acute psychoses, most of which 
evolve into other disorders on follow-up,16,17 and the nearly 
incoherent group of major depressive disorders.18,19 At the 
level of clinical practice, there is a strong temptation to 
simplify and generalize. To an antipsychotic, antidepressant, 
or mood-stabilizing hammer, many conditions look like 
nails. And yet, efforts to differentiate and optimize drug 
responses among clinical conditions or clinically defined 
types of patients remain primitive or ignored. Pressures to 
maintain broad, relatively nonspecific, markets for various 
types of psychotropics have been very high, as noted by 
Dr Vázquez.5 It has been tempting for both the 
pharmaceutical industry and psychiatric clinicians to 
ascribe great weight to findings of statistically significant 
improvements  in  randomized,  placebo-controlled  trials. 
Indeed, the early years of modern psychopharmacology 
were at the forefront of development of current standard 
methods of design and analysis of controlled, clinical 
therapeutic trials. The problem is that most findings arise 
(quite appropriately) from trials designed to gain regulatory 
approval  and  to  pursue  the  aims  of  a  marketing  plan, 
rather than to inform and refine rational clinical practice. 
Ironically, massive treasures of information about clinical 
subtypes of patients who did especially well or poorly with 
a given treatment, or tolerated it especially well or poorly, 
remain in computer banks held as proprietary information 
by pharmaceutical manufacturers, and left minimally 
evaluated by clinical investigators of all kinds. A far more 
sophisticated body of information is needed to inform and 
guide sound clinical practice. This information reasonably 
can include information on clinical subtypes and a more 
refined set of expectations of what a given treatment can 
reasonably be expected to do.
Dr Vázquez5  identifies  additional  factors  that  limit  the 
ability of contemporary therapeutics research to contribute 
to a more sophisticated, specific, and predictable application 
of the available medicines that Dr Gardner4 challenges us to 
use more wisely. These include the tendency to generalize 
from averaged findings obtained with highly selected, often 
clinically unrepresentative, patient-subjects in therapeutic 
trials, and to make averages of averages in the currently 
enthusiastic application of data-pooling by the methods 
of meta-analysis. This kind of therapeutics research can 
usually identify useless or grossly intolerable compounds, 
but can hardly be expected to produce refined guidance for 
such basic clinical questions as which drug to start with 
and in what doses and for how long and for whom . . . and 
then  what?  In  addition  to  excessive  generalization  (for 
example, all forms of depression respond well and safely 
to antidepressants; antipsychotics are adequate treatment 
for all manifestations of schizophrenia), there is a tendency 
to overvalue or exaggerate the therapeutic efficacy of most 
psychotropics. In turn, such exaggerated expectations may 
arise from overvaluing probability values in comparisons 
of active drugs and placebos, rather than to attend to more 
relevant  effect  sizes  (difference  in  drug,  compared  with 
placebo, response divided by variance of measurement).
Regarding such outcome measures, there is both good 
and  bad  news.  Reassuring  news  includes  findings  of  a 
recent, ambitious, and scholarly comparison of effect 
sizes of psychotropics to medicines employed in general 
medicine,  which  found  relatively  favourable  results 
for many psychotropics.20 Not so good are clinically 
apparent tendencies to expect more of antipsychotics, 
antidepressants, mood stabilizers, or anxiolytics than 
they may deliver clinically with individual patients. Drug 
superiorities to placebo controls are typically in the range of 
30% to 50%, often with impressive P values (which can be 
engineered to assure success of even a marginally effective www.LaRCP.ca 404   W   La Revue canadienne de psychiatrie, vol 59, no 8, août 2014
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treatment provided that the number of subjects is high21). 
For  example,  antidepressants  may  average  30%  to  40% 
higher rates of response than a randomly assigned placebo 
treatment, but such numbers can be misleading. Rarely 
do trial outcomes represent full clinical, symptomatic, or 
functional recovery. Instead, they typically involve changes 
in standardized rating scale scores (which may or may not 
be adequate surrogates for clinical assessment), usually aim 
for improvements as low as 50%, are carried out only for 
perhaps 6 or 8 weeks, and involve highly selected subjects 
who may not adequately represent clinically encountered 
patients with nominally similar diagnoses. Rather, similar 
averaged outcomes within any class of psychotropics are 
virtually inevitable as drugs would not be marketed if not 
superior to placebo in at least 2 (of sometimes numerous) 
trials.  Indeed,  it  has  proved  difficult  to  demonstrate 
substantial, credible, and clinically meaningful differences 
between  specific  drugs  within  a  given  class  in  terms  of 
efficacy and tolerability, whether they be antidepressants, 
anxiolytics, antipsychotics, or proposed mood 
stabilizers.22–24 Overall, despite their limitations, available 
averaged outcomes for most types of clinically employed 
psychotropics are generally favourable. Nevertheless, such 
evidence is far from being a sound basis on which to assume 
that the work of modern psychiatric therapeutics is simply 
to pick the right drug and an approximately appropriate 
dose for a given patient.
In addition, evidence for long-term effectiveness of most 
types  of  psychotropics  in  providing  sustained  benefits 
and protection from recurrences of psychiatric illnesses 
remains particularly limited and often based on ambiguous 
research methods.1 These include the potentially biasing 
selection of patients who respond, short term, to a given 
drug-product (whose manufacturer typically sponsors the 
trial) to continue (relatively briefly in comparison to the 
natural history of recurrence patterns) into aftercare that 
often involves randomized discontinuation to a placebo—
that is, removing an apparently effective treatment, often 
with incomplete recovery from an acute illness. Such trial 
designs can add drug-discontinuation stress to factors 
associated with relapses or recurrences of illness, and 
so  inflate  apparent  drug–placebo  differences.25,26 Drug 
discontinuation can not only confound interpretation 
of  long-term  treatment  trials  but  also  sometimes  have 
potentially dangerous, adverse effects on clinical treatment. 
Such  risks  are  particularly  evident  in  pregnancy,  when 
many women and their physicians are more concerned with 
usually hypothetical or rare teratogenic effects than with 
common and major adverse effects on maternal health, and 
their unknown effects on the developing fetus.27,28
A striking consequence arises from the evidently widely 
accepted  belief  that  psychotropics  routinely  provide 
major clinical benefits and that a solution to most clinical 
problems can be found with the right drug or combination 
of drugs at the right doses. Such beliefs encourage 
what can be termed an allopathic compulsion to pursue 
pharmacological treatments relentlessly, uncritically, often 
rather thoughtlessly, and potentially dangerously. Moreover, 
given substantial risks of failure and high rates of partial 
or  temporary  symptomatic  improvements  with  standard 
psychotropic  treatments  given  in  monotherapy,  there  is 
a  growing  temptation  to  try  imaginative  combinations 
or agents, higher than recommended doses, or to add 
unconventional  treatments  that  lack  regulatory  approval 
for psychiatric applications. Most such practices appear to 
be responses to patient and clinician frustrations with lack 
of  substantial  clinical  improvement.  Even  though  some 
such efforts are often understandable, almost always, they 
lack specific scientific testing for added effectiveness with 
acceptable safety.29–32
Given the appreciable limitations of modern psychotropic 
medicines  to  solve  the  complex  human  problems 
represented by most cases of psychiatric illness, it 
seems especially ironic that much of what psychiatry 
learned during the past 2 centuries—including efforts to 
develop  descriptive  nosologies,  and  psychopathological 
as well as psychodynamic understanding of people with 
psychiatric  illness—appears  to  have  become  devalued 
in  the  competition  with  seemingly  simple,  effective, 
supposedly  even  sufficient,  and  certainly  cost-effective, 
pharmacologically  based  treatments.  This  view  of 
psychiatry is strongly encouraged by currently pervasive 
interest  in  savings  of  costs,  time,  and  effort  in  this  era 
of  managed  care. As  has  occurred  with  many  previous 
movements in psychiatry (descriptive, psychopathological, 
neuromedical, psychodynamic, community psychiatry, and 
others), psychopharmacology is currently overvalued, and 
at long-term risk of being devalued or even abandoned, too. 
As noted by Dr Vázquez,5 an increasingly ominous trend in 
psychiatric clinical practice and in training programs, is the 
difficulty to engage in curiosity. The decline of curiosity has 
been encouraged by increasing pressures to produce more 
units of clinical product per hour, to save as much time and 
cost as possible, and to avoid asking questions that may 
seem to complicate understanding or care of a patient.
In summary, modern psychopharmacology has brought 
clinical  benefits  that  have  truly  revolutionized  modern 
psychiatry. It also has had a profound impact on nosology 
and theories of psychiatric illnesses, on hypotheses for 
psychiatric research, as well as on the training of mental 
health clinicians and the organization of contemporary 
mental  health  services.  Nevertheless,  it  has  led  to  some 
notable, unintended, adverse consequences. These appear to 
arise from overestimating and overvaluing the effectiveness 
and tolerability of psychotropic treatments, sometimes with 
relentless pursuit of increasingly complex, aggressive, and 
nonrational  treatment  regimens  whose  value  and  safety 
are untested. Consequences of the domination of modern 
psychiatric therapeutics by drug treatments include wide 
disparities in the quality of patient assessment, treatment, 
and follow-up care, surely encouraged by cost-containment 
efforts throughout clinical medicine. There is a particularly 
lamentable threat to the tradition of thoughtfulness, www.TheCJP.ca The Canadian Journal of Psychiatry, Vol 59, No 8, August 2014   W   405
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thoroughness, and curiosity that has evolved during the past 
2 centuries of progress in psychiatry.
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